ISI Stock Overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ionis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.56 |
| 52 Week High | US$47.71 |
| 52 Week Low | US$30.06 |
| Beta | 0.35 |
| 1 Month Change | -7.12% |
| 3 Month Change | -11.05% |
| 1 Year Change | -32.30% |
| 3 Year Change | 6.30% |
| 5 Year Change | -43.42% |
| Change since IPO | -12.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| ISI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.1% | 2.3% | 0.5% |
| 1Y | -32.3% | -2.6% | 15.3% |
Return vs Industry: ISI underperformed the German Biotechs industry which returned -4.6% over the past year.
Return vs Market: ISI underperformed the German Market which returned 13.7% over the past year.
Price Volatility
| ISI volatility | |
|---|---|
| ISI Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ISI has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ISI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 927 | Brett Monia | www.ionis.com |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
Ionis Pharmaceuticals, Inc. Fundamentals Summary
| ISI fundamental statistics | |
|---|---|
| Market cap | €5.04b |
| Earnings (TTM) | -€345.43m |
| Revenue (TTM) | €773.11m |
6.4x
P/S Ratio-14.4x
P/E RatioIs ISI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISI income statement (TTM) | |
|---|---|
| Revenue | US$803.07m |
| Cost of Revenue | US$917.98m |
| Gross Profit | -US$114.91m |
| Other Expenses | US$243.90m |
| Earnings | -US$358.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
| Earnings per share (EPS) | -2.27 |
| Gross Margin | -14.31% |
| Net Profit Margin | -44.68% |
| Debt/Equity Ratio | 275.7% |
How did ISI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 10:00 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ionis Pharmaceuticals, Inc. is covered by 47 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |
| James Birchenough | Barclays |